13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001778253
Total reported value
$928.2M
$928.2M
139 檔
46.7%
At the close of Q1 2026, Ikarian Capital, LLC disclosed equity holdings valued at approximately $928.2M, spread across 139 reported holdings.
Ikarian Capital, LLC executed strategic sector rebalancing during Q1 2026, establishing 24 new positions while fully exiting 33 holdings and trimming 19 positions.
In terms of portfolio concentration, the top 5 core holdings (including 430, XBI, CYTK) accounted for 46.7% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 11.37% | -11.37% | EXIT | |
| 2 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 8.30% | -3.19% | -5.88% | |
| 3 | CYTK | Cytokinetics Inc | Stock-Healthcare | 6.65% | -6.65% | EXIT | |
| 4 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 4.69% | -4.69% | EXIT | |
| 5 | KOD | Kodiak Sciences Inc | Stock-Other | 4.23% | +1.13% | +89.75% | |
| 6 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 4.03% | -4.03% | EXIT | |
| 7 | ABVX | Abivax Sa-adr | Stock-Other | 3.16% | +10.00% | +6.00% | |
| 8 | ALMS | Alumis Inc | Stock-Other | 2.64% | +1.08% | +600.21% | |
| 9 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 2.46% | -2.20% | — | |
| 10 | CAPR | Capricor Therapeutics Inc | Stock-Other | 2.17% | +0.31% | +51.90% | |
| 11 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.04% | -2.04% | EXIT | |
| 12 | PCVX | Vaxcyte Inc | Stock-Other | 2.02% | +0.41% | +13.20% | |
| 13 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.87% | +1.51% | -17.32% | |
| 14 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.85% | +0.58% | +258.80% | |
| 15 | HROW | Harrow Inc | Stock-Other | 1.55% | -0.93% | -21.64% | |
| 16 | RLMD | Relmada Therapeutics Inc | Stock-Other | 1.52% | +0.08% | -12.38% | |
| 17 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.48% | +0.90% | — | |
| 18 | TENX | Tenax Therapeutics Inc | Stock-Other | 1.47% | +0.38% | +16.98% | |
| 19 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.46% | +4.52% | -19.38% | |
| 20 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.39% | -0.60% | +19.76% | |
| 21 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.32% | -0.86% | — | |
| 22 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 1.19% | -1.19% | EXIT | |
| 23 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 1.16% | -1.16% | EXIT | |
| 24 | PHVS | Pharvaris N.V. | Stock-Other | 1.12% | +0.03% | — | |
| 25 | ✓ | Connect Biopharma Hldgs LTD | Stock-Other | 1.10% | +0.06% | +12.16% | |
| 26 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.99% | -0.32% | +4.53% | |
| 27 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.96% | -0.96% | EXIT | |
| 28 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.95% | +0.27% | -38.98% | |
| 29 | ANRO | Alto Neuroscience Inc | Stock-Other | 0.94% | +0.22% | — | |
| 30 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.94% | -0.94% | EXIT | |
| 31 | VERA | Vera Therapeutics Inc | Stock-Other | 0.89% | +0.87% | — | |
| 32 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.86% | +0.57% | +185.59% | |
| 33 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.82% | -0.22% | -6.80% | |
| 34 | EYPT | Eyepoint Inc | Stock-Other | 0.78% | +0.36% | — | |
| 35 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 0.71% | -0.13% | +99.14% | |
| 36 | DMRA | Damora Therapeutics Inc | Stock-Other | 0.71% | +0.23% | +17.50% | |
| 37 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.68% | -0.50% | +527.76% | |
| 38 | PVLA | Palvella Therapeutics Inc | Stock-Other | 0.65% | -0.65% | EXIT | |
| 39 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.65% | -0.24% | -23.72% | |
| 40 | SPRB | Spruce Biosciences Inc | Stock-Other | 0.64% | +0.07% | — | |
| 41 | IVA | Inventiva SA - Adr | Stock-Other | 0.64% | -0.19% | +184.34% | |
| 42 | JBIO | Jade Biosciences Inc | Stock-Other | 0.58% | +0.44% | +70.78% | |
| 43 | OCGN | Ocugen Inc | Stock-Other | 0.58% | +0.07% | — | |
| 44 | ✓ | Zura Bio LTD | Stock-Other | 0.58% | +0.19% | +48.75% | |
| 45 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.52% | +0.14% | +1069.30% | |
| 46 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.49% | -0.49% | EXIT | |
| 47 | ✓ | Uniqure NV | Stock-Other | 0.47% | -0.22% | +236.81% | |
| 48 | ACOG | Alpha Cognition Inc | Stock-Other | 0.47% | +0.18% | — | |
| 49 | PTHS | Pelthos Therapeutics Inc | Stock-Other | 0.44% | +0.34% | +0.33% | |
| 50 | SRZN | Surrozen Inc | Stock-Other | 0.41% | -0.41% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | +6.3% | +66.40% | Add |
| 2 | CYTK | Cytokinetics Inc | +4.4% | +168.02% | Add |
| 3 | KOD | Kodiak Sciences Inc | +2.7% | +89.75% | Add |
| 4 | ALMS | Alumis Inc | +2.5% | +600.21% | Add |
| 5 | ANIP | Ani Pharmaceuticals Inc | +1.3% | +258.80% | Add |
| 6 | CAPR | Capricor Therapeutics Inc | +0.9% | +51.90% | Add |
| 7 | KPTI | Karyopharm Therapeutics Inc | +0.9% | +372.58% | Add |
| 8 | PCVX | Vaxcyte Inc | +0.7% | +13.20% | Add |
| 9 | CTNM | Contineum Therapeutics Inc-a | +0.6% | +185.59% | Add |
| 10 | RVMD | Revolution Medicines Inc | +0.6% | +10.72% | Add |
| 11 | AVTX | Avalo Therapeutics Inc | +0.6% | +527.76% | Add |
| 12 | TENX | Tenax Therapeutics Inc | +0.6% | +16.98% | Add |
| 13 | OVID | Ovid Therapeutics Inc | +0.5% | +1069.30% | Add |
| 14 | IVA | Inventiva SA - Adr | +0.5% | +184.34% | Add |
| 15 | RLMD | Relmada Therapeutics Inc | +0.4% | -12.38% | Trim |
| 16 | EPRX | Eupraxia Pharmaceuticals Inc | +0.4% | +99.14% | Add |
| 17 | SRZN | Surrozen Inc | +0.3% | +163.13% | Add |
| 18 | ✓ | Uniqure NV | +0.3% | +236.81% | Add |
| 19 | ✓ | Zura Bio LTD | +0.3% | +48.75% | Add |
| 20 | JBIO | Jade Biosciences Inc | +0.2% | +70.78% | Add |
| 21 | ANRO | Alto Neuroscience Inc | +0.2% | — | Unchanged |
| 22 | XBI | Ss Spdr S&p Biotech ETF | +0.2% | -5.88% | Trim |
| 23 | LPCN | Lipocine Inc | +0.2% | +154.86% | Add |
| 24 | DMRA | Damora Therapeutics Inc | +0.2% | +17.50% | Add |
| 25 | ANNX | Annexon Inc | +0.2% | +152.01% | Add |
| 26 | ABOS | Acumen Pharmaceuticals Inc | +0.2% | +314.37% | Add |
| 27 | ALEC | Alector Inc | +0.1% | — | Unchanged |
| 28 | BHVN | Biohaven Ltd. | +0.1% | +94.13% | Add |
| 29 | CMPS | Compass Pathways PLC | +0.1% | +68.75% | Add |
| 30 | LABD | Dire Dly Sp Bt Be 3x Etf-usd | +0.1% | +159.23% | Add |
| 31 | PHVS | Pharvaris N.V. | +0.1% | — | Unchanged |
| 32 | CABA | Cabaletta Bio Inc | +0.1% | — | Unchanged |
| 33 | TRAW | Traws Pharma Inc | 0% | — | Unchanged |
| 34 | VTLUSD | Immunic Inc | 0% | — | Unchanged |
| 35 | DRUG | Bright Minds Biosciences Inc | 0% | +4.53% | Add |
| 36 | NMRA | Neumora Therapeutics Inc | 0% | — | Unchanged |
| 37 | 4XC1 | Kalvista Pharmaceuticals Inc | 0% | — | Unchanged |
| 38 | DBVT | Dbv Technologies Sa-spon Adr | 0% | — | Unchanged |
| 39 | ✓ | Connect Biopharma Hldgs LTD | 0% | +12.16% | Add |
| 40 | EQ | Equillium Inc | 0% | — | Unchanged |
| 41 | 2KZ0 | Kezar Life Sciences Inc | 0% | — | Unchanged |
| 42 | MGNX | Macrogenics Inc | 0% | — | Unchanged |
| 43 | LXRX | Lexicon Pharmaceuticals Inc | 0% | — | Unchanged |
| 44 | PHGE | Biomx Inc | 0% | — | Unchanged |
| 45 | IBIO | Ibio Inc | 0% | — | Unchanged |
| 46 | NEUP | Neuphoria Therapeutics Inc | 0% | — | Unchanged |
| 47 | STIM | Neuronetics Inc | — | — | Unchanged |
| 48 | PURR | Hyperliquid Strategies | — | — | Unchanged |
| 49 | ✓ | Immatics NV | — | — | Unchanged |
| 50 | FTH | Faeth Therapeutics Inc | — | -70.25% | Trim |
According to official SEC Form 13F filings, Ikarian Capital, LLC reported a total U.S. public equity portfolio value of $928.2M across 139 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
QQQ
市值: $57.7M
Top Position Liquidated / Trimmed
CDTX
前期市值: $126.6M
During Q1 2026, Ikarian Capital, LLC's top holdings by market value included 430 (11.4%)、XBI (8.3%)、CYTK (6.7%). The largest single position, 430, represented 11.4% of total portfolio value.
In Q1 2026, Ikarian Capital, LLC made 108 total portfolio adjustments, initiating 24 new buys, adding to 32 positions, trimming 19 holdings, and fully liquidating 33 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.